News on Mendelian diseases, hereditary cancer, variant classification, cystic fibrosis testing and more.
Boston-based Variantyx will expand its whole-genome sequencing testing method to oncology from rare inherited and neurological disorders.
The tools are part of Molecular Health's MH Guide platform, which analyzes sequencing data to identify and report on disease-related gene variants.
As adoption of personalized medicines has accelerated over the last four years, so has the number of marketed genetic and exome tests.
Sebia and Janssen Biotech collaborated on the development of the test, which is for assessing patients treated with Darzalex.
